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Single nucleotide polymorphisms 
in LCAT may contribute 
to dyslipidaemia in HIV‑infected 
individuals on HAART 
in a Ghanaian population
Simon Bannison Bani1,6, Kwabena Owusu Danquah3,6, Christian Obirikorang2,6*, 
William K. B. A. Owiredu2, Lawrence Quaye1, Edmund Muonir Der4, 
Emmanuel Acheampong2,5, Yussif Adams1, Peter Paul M. Dapare1, Moses Banyeh1, 
Enoch Odame Anto3,5 & Samuel Asamoah Sakyi2
Highly active antiretroviral therapy (HAART) is known to cause lipid abnormalities such as 
dyslipidaemia in HIV‑infected individuals. Yet, dyslipidaemia may not independently occur as it may 
be worsened by single nucleotide polymorphisms (SNPs) in lecithin cholesterol acyltransferase (LCAT) 
and lipoprotein lipase (LPL). This case–control study was conducted in three‑selected hospitals in 
the Northern part of Ghana. The study constituted a total of 118 HIV‑infected participants aged 
19–71 years, who had been on HAART for 6–24 months. Dyslipidaemia was defined based on the 
NCEP‑ATP III criteria. HIV‑infected individuals on HAART with dyslipidaemia were classified as cases 
while those without dyslipidaemia were grouped as controls. Lipid profile was measured using an 
automatic clinical chemistry analyzer and genomic DNA was extracted for PCR (GeneAmp PCR 
System 2700). Overall, the prevalence of dyslipidaemia was 39.0% (46/118). High levels of low‑
density lipoprotein cholesterol (LDL‑C), total cholesterol (TC), and reduced levels of high‑density 
lipoprotein cholesterol (HDL‑C) were observed in all cases. A total of 256 selected PCR amplicons 
comprising 137 LPL (exons 3, 5 and 6) and 119 LCAT (exons 1, 4, and 6) were sequenced in 46 samples 
(Inqaba Biotech). Six (6) clinically significant SNPs were identified in exons 1 and 4 for LCAT whereas 
25 non‑clinically significant SNPs were identified for LPL in exons 5 and 6. At position 97 for LCAT 
exon 1, there was a deletion of the nucleotide, ‘A’ in 32.5% (13/40) of the sampled population while 
67.5% (27/40) of the sample population retained the nucleotide, ‘A’ which was significantly associated 
with dyslipidaemic outcomes in the study population (p = 0.0004). A total of 25 SNPs were identified 
in exons 5 and 6 of LPL; 22 were substitutions, and 3 were insertions. However, none of the 25 
SNPs identified in LPL exon 5 and 6 were statistically significant. SNPs in LCAT may independently 
contribute to dyslipidaemia among Ghanaian HIV‑infected individuals on HAART, thus, allowing 
genetic and/or functional differential diagnosis of dyslipidaemia and creating an opportunity for 
potentially preventive options.
The incidence of human immunodeficiency virus (HIV) epidemic in Ghana is low with heterogeneously high 
prevalence in some key ethnic  populations1,2. The prevalence rate of HIV among individuals within the ages 
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of 15–49 years in Ghana has reduced from 2.3% in 2013 to 1.7% in 2018 with regional variation per the World 
Bank collection of development  indicators1–3. The longevity of HIV patients has increased significantly in the 
past two decades due to the introduction of antiretroviral treatment (ART) as the gold standard  treatment4,5.
In the management of HIV-infected individuals, highly active antiretroviral therapy (HAART) has been 
shown to significantly reduce HIV viral load, prevent the development of acquired immune deficiency syndrome 
(AIDS) and lower HIV related morbidity and  mortality6. The current regimen is made up of two nucleotide 
reverse transcriptase inhibitors (NRTI) plus one non-nucleotide reverse transcriptase inhibitor (NNRTI) or two 
NRTI plus one protease inhibitor (PI)7–9. Despite the benefits derived from the use of HAART, there have been 
reports indicating that long-term usage of HAART induces significant adverse cardiometabolic and cardiovas-
cular events such as dyslipidaemia, insulin resistance, central adiposity and  lipodystrophy10,11. Among these 
events, dyslipidaemia has commonly been associated with prolonged use of HAART thus, increasing the risk of 
atherosclerosis and cardiovascular disease among HIV infected  individuals12,13.
Generally, HIV-infected individuals experience a reduced level of high-density lipoprotein (HDL) choles-
terol and low-density lipoprotein (LDL) cholesterol, and subsequently by a raised in plasma triglyceride (TG) 
in the years before they develop  AIDS14,15. Even though it is known that prolong HAART use can result in 
dyslipidaemia, regular monitoring of lipids profile in HIV infected patients on HAART is not a conventional 
practice in Ghana, thus exposing infected individuals to a potentially high-risk metabolic and cardiovascular 
 complications15. Abnormal metabolism of lipids leads to dyslipidaemia and others to atherosclerotic events that 
clinically manifest as coronary heart disease, myocardial infarction, and  stroke16,17.
The metabolism of lipids is mediated by the enzymes, lecithin cholesterol acyltransferase (LCAT), and lipo-
protein lipase (LPL). LCAT mediates the maturation of high-density lipoprotein (HDL) and reverses the trans-
portation of cholesterol while LPL cleaves fatty acid and monoacylglycerol from triglycerides  metabolism18. 
Alterations in the structure and function of these enzymes are also reported to affect the metabolism of lipids 
and lead to  dyslipidaemia19,20. While abnormal lipid accumulation can be caused by both familial and secondary 
factors, little attention has been given to familial or functional cause of dyslipidaemia induced by HAART among 
HIV/AIDs infected individual in Ghana One way to assess the familial or genetic variations of the individual 
population is by employing the concept of single nucleotide polymorphism (SNPs).
SNPs have been recognised as one of the most prominent causes of mutations in these enzymes which pre-
dispose carriers to the development of dyslipidaemia and the resultant negative metabolic  sequelae19. Previous 
prospective  studies14,21 that found associations between apo A-V polymorphism and the development of dyslipi-
daemia in HIV infected individuals on HAART suggested that polymorphism genotyping could help identify 
prospective HAART patients who are at risk of developing  dyslipidaemia22,23.
Recently, a study by Obirikorang et al. demonstrated the presence of SNPs in four candidate genes (ABCA1-
rs2066714, LDLR-rs6511720, APOA5-rs662799, and DSCAML1-rs10892151) among HIV-infected individual 
on ART in a Ghanaian  population24. The authors found an association between variants in APOA5-rs662799 
polymorphisms and  dyslipidaemia24. These studies provide evidence that long-term use of ART coupled with 
SNPs potentiate the development of dyslipidaemia among HIV infected individual. To minimize the effect of 
duration on HAART for dyslipidaemia and to explore the involvement of SNPs in dyslipidaemia among HIV 
infected individuals, we sequenced a total of 256 selected PCR amplicons, comprising 137 LPL (exons 3, 5 and 
6) and 119 LCAT (exons 1, 4 and 6) among HIV-infected patients on HAART who developed dyslipidaemia 
within the two year period in a Ghanaian population.
Methods
Study design and population. This hospital-based case–control study among HIV-infected patients was 
undertaken from October 2016 to December 2019 at three-selected hospitals in the Northern region [Tamale 
West Hospital (TWH), Tamale Central Hospital (TCH) and the Tamale Teaching Hospital (TTH). The Commit-
tee for Human Publication and Research Ethics of the Kwame Nkrumah University of Science and Technology, 
Kumasi Ghana (ref/CHRPE/AP/367/16) and the Institutional Review Committee of the Ghana Health Service 
in the Northern region (ref/GHS/NR/18-0) approved the study protocol. Written informed consent in a form 
of signature or thumbprint was obtained from all participants, and confidentiality was assured. The study was 
conducted under the conditions of the declaration of Helsinki for human research.
Sample size and selection of participants. Using an effect size of 0.31 in reference to finding from 
previous  study24, and given an alpha (α) value of 0.05, 95% confidence interval, a power of detecting a statisti-
cally significant difference between two groups, based on the goodness-of fit tests  (X2-test), the required total 
calculated sample size was 206. A cohort of 300 HIV-infected individuals was initially recruited using the medi-
cal records available at the Anti-Retroviral Treatment (ART) Centre.
Age, gender, date of the first diagnosis, weight, blood pressure measurement, and type of HAART were 
retrieved from medical records available at the Anti-Retroviral Treatment (ART) Centre using a well-structured, 
self-designed questionnaire. These questionnaires were pre-tested among 10 persons living with HIV adminis-
tered and on HAART to clear possible ambiguity and difficulty in answering the questions.
Inclusion and exclusion criteria. Long-term use of ART has been demonstrated to exponentiate the 
development of dyslipidaemia among HIV infected individual. To investigate the role of SNPs in dyslipidae-
mia among HIV infected individuals while minimizing the effect of duration on HAART for dyslipidaemia, we 
included individuals who has been on HAART for at most two years. A total of 118 HIV-infected individuals 
who had been on HAART for 6–24 months were included in the final analysis for this study (Fig. 1). The antiret-
rovirals included Zidovudine (AZT), Lamivudine (3TC), efavirenz (EFV), Nevirapine (NVP), Tenofovir (TDF), 
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Lopinavir (LPV), NVP, Emtricitabine (FTC) and Ritonavir (r). These drugs were administered as triple combina-
tions as follows; AZT/3TC/EFV, AZT/3TC/NVP, TDF/3TC/EFV, TDF/3TC/LPV, TDF/3TC/LPV/r, TDF/3TC/
NVP, TDF/FTC/EFV.
Conversely, of the 300 HIV-infected individuals recruited at baseline, 182 patients comprising 24 patients 
who had been of HAART for less than 6 months and 158 who were on lipid lowering drugs, had neurological 
disorder, were pregnant women, and had AIDS were excluded from the study.
Biochemical analysis. Venous blood sample (5  mL) was taken from these participants, 4  mL was dis-
pensed into a gel vacutainer tube for the estimation of serum lipids using a fully automatic chemistry analyzer 
(Vital Scientific Selectra Flexor XL, UK) while 1 mL was dispensed into EDTA vacutainer tube for DNA extrac-
tion for PCR analysis. The Friedewald’s formula, LDL-C = TC-(HDL-C-TG/2.2) was used for calculating LDL-C. 
Friedewald’s equation over miscalculates LDL-c when serum triglycerides (TG) are high, therefore subjects with 
TG ≥ 4.2 mmol/L were excluded from the study. This is to avoid potential bias affecting the association of LDL-C 
with dyslipidaemia.
Dyslipidaemia was defined in this study as the presence of at least two lipid abnormalities (i) hypertriglyc-
eridaemia—fasting serum triglyceride level ≥ 1.7 mmol/L (150 mg/dL), (ii) Reduced high density lipoprotein 
(HDL)-cholesterol, (iii) serum HDL-cholesterol ≤ 1.03 mmol/L (40 mg/dL) (males) or 1.29 mmol/L (≤ 50 mg/
dL) (females), (iv) high serum low density lipoprotein (LDL)-cholesterol ≥ 3.37 mmol/L (130 mg/dL) and (v) 
Figure 1.  Flowchart of study participants. TCH Tamale Central Hospital, TTH Tamale Teaching Hospital, 
TWH Tamale West Hospital.
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high total cholesterol ≥ 6.2 mmol/L (200 mg/dL) as defined by NCEP ATP  III25. Of the 118 participants, 46 HIV-
infected patients had dyslipidaemia and were classified as cases whereas 72 of them had no dyslipidaemia and 
were classified as controls (Fig. 1).
Selection of SNPs. Long-term usage of HAART is significantly associated with abnormal metabolism. To 
minimize the effect of the duration on HAART for dyslipidaemia and explore the role that SNPs play in dyslipi-
daemia among HIV infected individuals, two candidate SNPs (LCAT and LPL) were genotyped and sequenced 
among 46 HIV-infected patients who developed dyslipidaemia within the two years on being on HAART. These 
SNPs were selected based on reports from previous studies that demonstrate a significant association with dys-
lipidaemia following a review of PubMed reports and GWAS. Lecithin cholesterol acyltransferase (LCAT) medi-
ates the maturation of high-density lipoprotein (HDL) and reverses the transportation of cholesterol while lipo-
protein lipase (LPL) cleaves fatty acid and monoacylglycerol from  triglycerides18.
PCR conditions. All PCR reactions were performed using Mtaq polymerase, ddNTPs,  Mg2Cl3, Nuclease-
free sterile distilled water, genomic DNA, forward primer, reverse primer, and buffer. A total reaction volume of 
40 µL comprising 2 µL Taq polymerase (1 in 25 dilutions), 6 µl PCR buffer, 6 µL MgCl, 2 µL gDNA, 2 µL each 
of primer pairs at 10 µM, and 17 µL of Nuclease-free sterile distilled water was used. PCR was run using the fol-
lowing cycling conditions: an initial denaturation of 95 °C for 10 min; 35 cycles of 95 °C for 1 min, (Tma15°C) for 
1 min, and 68 °C for 2 min; a final extension of 68 °C for 10 min; and a holding temperature of 4 °C until the end 
of a run. All PCR runs were performed with GeneAmp PCR System 2700 following manufacturer’s protocols 
(Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA) (Table 1).
Figure 2 shows the various primer amplicons on agarose gel, along the DNA ladder (1000 bp). We designed 
primers that targeted exons 1, 4 and 6 in LCAT and exons 3, 5 and 6 in LPL, This full-length gel shows that, LCAT 
exon 6 is bigger than exon 1 and exon 1 is bigger than exon 4, since the smallest amplicon runs fasted (Fig. 2).
DNA sequencing. A total of 256 selected PCR amplicons comprising 137 LPL (exons 3, 5 and 6) and 119 
LCAT (exons 1, 4, and 6) samples were successfully sequenced at Inqaba Biotech, Pretoria, South Africa. DNA 
sequencing was done by the automated Sanger sequencing  method26. The PCR amplified products were puri-
fied and sequenced under standard conditions on the ABI 3500XL Genetic Analyzer (POP7, Big Dye 3.1). The 
sequencing data was analyzed using Variant Reporter version 1.0 (Applied Biosystems, Foster City, CA) and 
Sequencher version 4.8 (Gene Codes Corporation, Ann Arbor, MI) according to Inqaba Biotech, Pretoria, South 
Africa. The sequence results were received and analysed using Chromas, Technelysium DNA sequencing soft-
ware at https ://techn elysi um.com.au/wp/chrom as and multiple sequence alignment carried out using Clustalw 
at https ://www.genom e.jp/tools -bin/clust alw. Protein modelling was carried out using the ExPASy Bioinformat-
ics Resource Portal at https ://web.expas y.org/trans late (Supplementary Figs. S1–S4).
Statistical analysis. Data was entered into Microsoft excel 2016 and exported to GraphPad Prism version 
6.0 (www.graph pad.com) for analysis. Data was presented as numbers, percentages, means, and 95% confidence 
interval and, median and interquartile range. The Kolmogorov–Smirnov test was used to check the normal-
ity of the continuous variables. Parametric continuous were compared between groups using student paired 
t-test and expressed as mean (95% CI) while non-parametric variables were performed with the Mann–Whitney 
test and expressed as median (inter-quartile range). Logistic regression models were fitted to test for associa-
tions between dyslipidaemia and selected single SNP. After the sequencing and alignment, some participants 
had DNA sequence same as the reference sequence and were classified as such. Other participants had DNA 
sequences different from the reference sequence and were classified as the SNP population. A P < 0.05 was con-
sidered statistically significant.
Table 1.  Primer information. The designed primers were synthesized by Integrated DNA Technologies, 
Coralville, IOWA, United States (https ://eu.idtdn a.com/site, integrated DNA Technologies Inc, USA). LCAT 
lecithin cholesterol acyltransferase, LPL lipoprotein lipase, FP forward primer, RP reverse primer, TM melting 
temperature.
Primer name Primer sequence Amplicon size TM (℃)
LCAT exon 1 FP: 5′-GCT TTC TCT GGC AGT AGG CA-3′RP: 5′-TGG TGG GGG CTT ACC GAG -3′ 164
60.04
61.01
LCAT exon 4 FP: 5′-GTG CTG CTG GTC CCCC-3′RP: 5′-TCA TCC GCA GAG ACA CTC A-3′ 95
59.61
58.04
LCAT exon 6 FP: 5′-TGT CCC ACC TTG CTC CAT ATC-3′RP: 5′-TCA ACC TGA AAC ATA GCC ATCA-3′ 594
59.51
57.70
LPL exon 3 FP: 5′-AAA GCT TGT GTC ATC ATC TTC AGG -3′RP: 5′-CAC ATA AGT CTC CTT CTC CCAGT-3′ 180
59.54
59.23
LPL exon 5 FP: 5′-AAT TTA CAA ATC TGT GTT CCT GCT -3′RP: 5′-AGG ATA AGA GTC ACA TTT AAT TCG C-3′ 234
57.34
57.52
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Results
Table 2 shows a comparison between case and control subjects regarding demographic characteristics, weight 
measurement, haemodynamic and lipid parameters, and dyslipidaemic indices. In all, 39.0% (46/118) of the 
study population developed dyslipidaemia based on NCEP-ATPII definition and were classified as cases, while 
61.0 (72/118) were without dyslipidaemia and were classified as controls. There were more females than males 
(99 vs. 19). The mean duration of ART drugs was 16 months. The case-subjects were significantly weightier 
than the control-subjects [65.5 vs. 59.3 p = 0.0071]. Higher levels of triglyceride (p = 0.0439), TC (p < 0.0001), 
LDL-C (p < 0.0001), non-HDL-C (p < 0.0001) and VLDL-C (p = 0.0449) were found in case-subjects than the 
control-subjects. Compared to the case-subjects, control-subjects recorded significantly higher levels of HDL-C 
[0.7 vs. 1.5, p < 0.0001].
Figure 3 shows the distribution duration of HAART. The majority of the subjects had been on HAART 
between 18–24 months (45.8%) followed by 12–17 months (37.3%) and the least being 6–11 months (16.9%) 
respectively (Fig. 3).
Single nucleotide polymorphism identified in LCAT . The study identified 5 substitutional SNPs in 
LCAT exon 1. At position 86 of LCAT exon 1, A was substituted for C in 12.5% (5/40) of the sample popula-
tion while 87.5% (35/40) retained a C in the same position. This C → A nucleotide change did not significantly 
influence dyslipidaemia in the study population (p = 0.091). At position 89 of LCAT exon 1, A is substituted for 
G in 12.5% (5/40) of the sampled population while 87.5% (35/40) of the sampled population retained the G. 
This G → A SNP was not significantly associated with dyslipidaemia outcomes in HIV-infected individuals on 
HAART (p = 0.342). At position 97 of LCAT exon 1, there was a deletion of A in 32.5% (13/40) of the sampled 
population while 67.5% (27/40) of the sample population retained the A. This SNP was significantly associated 
with dyslipidaemic outcomes in the study population (p = 0.0004). At position 111, A was substituted for C in 
7.5% (3/40) of the sampled population, while 92.5% (37/40) of the population retained C. This C → A nucleo-
tide change was not significantly associated with dyslipidaemia in the study population (p = 0.231). Similarly, 
at position 121, 12.5% (5/40) of the study population expressed A while 87.5% (35/40) of the study population 
expressed C, this SNP was not significantly associated with dyslipidaemia in the study population (p = 0.342). 
Another SNP, a deletion of A was identified at position 8 of LCAT exon 4 in 91.3% (42/46) of the sampled popu-
lation while 8.7% (4/46) of the study population retained an A at the same position. The deletion of A at posi-
tion 8 of LCAT exon 4 was not significantly associated with dyslipidaemia outcomes in the sampled population 
(p = 0.990). No SNP was identified in LCAT exon 6 (Table 3).
Table 4 shows the types of nucleotide changes identified in LPL and their associations with dyslipidaemia in 
the study population. A total of 25 SNPs were identified in exons 5 and 6 of LPL; 22 were substitutions, and 3 
were insertions. At positions 1, 2 and 3 of LPL exon 3, 8.7% (4/46) of the sampled population had TTA while 
91.3% (42/46) of the study population had GCC. This SNP was not significantly associated with dyslipidaemia in 
the study population (p = 0.279). At positions 5 and 6, 8.7% (4/46) of the study population had AA while 91.3% 
Figure 2.  Results of ethidium bromide-stained full-length agarose gel electrophoresis visualized with UV light.
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(42/46) of the study population had GC. These GC → AA nucleotide changes at positions 5 and 6 of LPL exon 5 
were not significantly associated with dyslipidemia in the population sampled (p = 0.279).
At position 8 of LPL exon 5, 6.5% (3/46) of the sampled population had C inserted into their genomes, 8.7% 
(4/46) of the population had T inserted at the same position, while 85.8% (39/46) had neither C nor T inserted 
into their genomes. The insertion of C and T at position 8 of LPL exon 5 did not have any significant effect on 
dyslipidaemic outcomes in HIV infected individuals on HAART. No SNP identified in LPL exon 3 (Table 4).
Table 2.  General characteristics of study participants. Cases: HIV-infected patients with dyslipidemia, control: 
HIV-infected without dyslipidaemia, Data is presented mean (95% CI). a Fisher exact test, Dyslipidaemia 
was defined as the presence of having at least two lipid abnormalities based on the NCEP-ATP III criteria. 
Zidovudine (AZT), Lamivudine (3TC), efavirenz (EFV), Nevirapine (NVP), Tenofovir (TDF), Lopinavir 
(LPV), NVP, Emtricitabine (FTC) and Ritonavir (r). Dyslipidaemic indices are presented as frequency 
(percentage).
Variable Cases (n = 46) Controls (n = 72) P-value
Age (years) 42.3 (39.1–45.4) 37.5 (35.4–39.7) 0.0107
Gendera 0.9870
Male 7 (15.2) 12 (16.7)
Female 39 (84.8) 60 (83.7)
Duration of HAART (months) 15.6 (13.5–17.6) 15.7 (14.1–17.2) 0.9093
HAART regimen
AZT/3TC/EFV 1 (2.2) 1 (1.4) 0.9989
AZT/3TC/NVP 7 (15.2) 6 (8.3) 0.3662
TDF/3TC/EFV 34 (73.9) 59 (82.0) 0.3577
TDF/3TC/NVP 4 (8.7) 6 (8.3) 0.9989
Systolic blood pressure 110.9 (106.5–115.2) 110.6 (107.2–114.1) 0.9353
Diastolic blood pressure 82.1 (79.4–84.9) 78.6 (76.8–80.4) 0.0300
Weight (kg) 65.5 (61.6–69.4) 60.0 (53.5–70.0) 0.0071
Lipid parameters (mmol/L)
Total cholesterol 5.6 (5.3–5.8) 3.9 (3.6–4.2) < 0.0001
Triglycerides 1.5 (1.3–1.8) 1.2 (1.0–1.4) 0.0439
HDL-cholesterol 0.7 (0.6–0.8) 1.5 (1.4–1.6) < 0.0001
LDL-cholesterol 4.2 (4.0–4.4) 2.7 (2.5–2.9) < 0.0001
VLDL-cholesterol 0.7 (0.6–0.8) 0.6 (0.5–0.7) 0.0449
Coronary risk 14.9 (11.8–17.9) 12.7 (10.2–15.2) 0.2782
Non-HDL cholesterol 4.9 (4.7–5.1) 3.2 (3.0–3.4) < 0.0001
Dyslipidaemic indices
High triglycerides, n (%)a 13 (28.3) 16 (22.2) 0.5138
High total cholesterol, n (%)a 46 (100.0) 10 (13.9) < 0.0001
Low HDL-cholesterol, n (%)a 46 (100.0) 62 (86.1) < 0.0001
High LDL-cholesterol, n (%)a 46 (100.0) 16 (22.2) < 0.0001
Figure 3.  Distribution of the duration of HAART. Data are presented in frequency (n).
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SNPs identified in LCAT and their contributions to dyslipidaemia in the study population. A 
total of 5 SNPs were identified in LCAT exon 1 (at positions 86, 89, 97, 111) while 1 SNP was identified in LCAT 
exon 6, at position 121. At position 86 of LCAT exon 1, 12.5% of the samples collected have A in place of C 
present in the reference population. There was no statistically significant difference between the SNP popula-
tion and the reference population in relation plasma TC (p = 0.070), TG (p = 0.530), LDL-C (p = 0.490), VLDL-
C (p = 0.230) and CR (p = 0.156), respectively. The plasma HDL concentration was significantly higher in the 
SNP population compared with in the reference population (1.07 ± 0.25  mmol/L vs. 0.881 ± 0.523  mmol/L, 
p = 0.0004). At position 89 of LCAT exon 1, 12.5% of the sample population has A in place of G in 87.2% of the 
Table 3.  Types of nucleotide changes identified in LCAT, and their associations with dyslipidemia in the study 
population. Odds ratio for dyslipidaemia risk of the SNPs identified in LCAT exon 1 and 4. REF reference, 
SEQ sequence, OR odds ratio, CI confidence interval, del deletion, ∆ change, Data are presented as discrete, 
fractions and percentages. P-values < 0.05 considered statistically significant. Reference population were 
defined as individuals with ‘normal’ nucleotide sequenced whereas SNP population were those with nucleotide 
changes.
Mutation ∆ Exon Position Ref Seq (frequency) SNP Seq (frequency) OR (95% CI) P-value
Substitution
1
86 C (33/40, 87.5%) A (7/40, 12.5%) 8.143 (0.898–97.551) 0.091
Substitution 89 G (35/40, 87.5%) A (5/40, 12.5%) 0.211 (0.021–2.079) 0.341
Deletion 97 A (27/40, 67.5%) del (13/40, 32.5%) 28.500 (3.155–57.400) 0.0004
Substitution
4
111 C (37/40, 92.5%) A (3/40, 7.5%) 8.200 (0.396–16.990) 0.231
Substitution 121 C (35/40, 87.5%) A (5/40, 12.5%) 4.750 (0.481–46.910) 0.341
Deletion 8 A (4/46, 8.7%) del (42/46, 91.3%) 0.500 (0.041–6.086) 0.999
Table 4.  Types of nucleotide changes identified in LPL, and their associations with dyslipidaemia in the 
study population. Odds ratio for dyslipidaemia risk of the various SNPs identified in LPL. SEQ sequence, 
FREQ Frequency, REF Reference, ∆ change, OR Odds ratio, LPL lipoprotein lipase. Data are presented as 
discrete, fractions and percentages. P-values < 0.05 considered statistically significant. Reference population 
were defined as individuals with ‘normal’ nucleotide sequenced Whereas SNP population were those with 
nucleotide changes. SNPs identified in LCAT and their contributions to dyslipidaemia in the study population.
Mutation ∆ Exon Position Ref seq frequency SNP seq frequency OR (95% CI) P-Value
Insertion 5
8 (39/46, 84.8%) C (3/46, 6.5%) 3.86 (0.17–87.20) 0.502
T (4/46, 8.7%) 5.40 (0.26–11.37) 0.261
27, 28, 29 (42/46, 91.3%) TAC (4/46, 8.7%) 4.85 (0.23–10.17) 0.279
Substitution 6
1, 2, 3 GCC (42/46, 91.3%) TTA (4/46, 8.7%) 4.85 (0.23–10.17) 0.279
5, 6 CG (42/46, 91.3%) AA (4/46, 8.7%) 4.85 (0.23–10.17) 0.279
9,10,11,12 GTCG (43/46, 94.3%) CATG (3/46, 6.5%) 3.29 (0.15–74.06) 0.519
14 C (42/46, 91.4%) T (4/46, 8.7%) 4.85 (0.23–10.17) 0.279
15 T (43/46, 94.3%) C (3/46, 6.5%) 3.29 (0.15–74.06) 0.519
17 T (39/46, 85.8%) G (3/46, 6.5%) 3.86 (0.17–87.20) 0.502
C (4/46, 8.7%) 5.40 (0.26–113.7) 0.26
20 C (39/46, 85.8%) A (3/46, 6.5%) 3.86 (0.17–87.20) 0.502
G (4/46, 8.5%) 5.40 (0.26–113.7) 0.260
21 C (43/46, 94.3%) A (3/46, 6.5%) 3.29 (0.14–74.06) 0.519
23 G (42/46, 91.5%) A (4/46, 8.7%) 4.85 (0.23–101.7) 0.279
33 C (42/46, 91.5%) T (4/46, 8.7%) 4.85 (0.23–101.7) 0.279
39 T (43/46, 94.3%) G (3/46, 6.5%) 3.29 (0.15–74.11) 0.519
41, 42, 43, 44, 45 GTAGA (40/46, 87.0%) GTATG (3/46, 6.5%) 0.11 (0.005–2.55) 0.148
ACCCG (3/46, 6.5%) 0.11 (0.005–2.55) 0.148
47, 48, 49 GTC (40/46, 87.0%) TAA (3/46, 6.5%) 2.56 (0.11–58.40) 0.990
GAC (3/46, 6.5%) 0.10 (0.004–2.34) 0.133
16 T (40/43, 93.0%) G (3/43, 7.0%) 0.103 (0.005–2.14) 0.089
80 A (41/43, 95.3%) T (2/43, 4.7%) 5.00 (0.22–11.50) 0.489
86 C (35/43, 81.6%) T (8/43, 18.6%) 1.18 (0.23–6.13) 0.990
96 T (39/43, 90.7%) A (4/43, 9.3%) 9.51 (0.47–19.01 0.110
190 C (41/43, 95.3%) T (2/43, 5.1%) 4.74 (0.21–105.6) 0.489
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study population. There was no statistically significant difference between the SNP and the reference population 
for the lipid parameters (p > 0.05) (Table 5).
Discussion
HAART administration interferes with triglyceride-rich lipoprotein hydrolysis by interfering with its binding 
to lipoprotein lipase, thereby hindering normal chylomicron, LDL, VLDL catabolism, trapping of fatty acids 
in peripheral adipose tissues and use by  muscles27. HAART also interferes with the degradation of the nuclear 
transcriptionally active factor SREBP1 (nSREBP1), which is the master transcription control protein involved 
in plasma lipid  synthesis27,28. The nSREBP1, therefore, lingers in the nucleus and continuously stimulate the 
transcription and translation of genes involved in the lipid biosynthesis  pathway29,30.
The prevalence of dyslipidaemia observed in the present study was 39.0%, which is consistent with cross-sec-
tional studies and case–control studies in Ghana and other  populations24,31–33. In the present study, dyslipidaemia 
was defined by increased plasma total cholesterol, LDL-C and decreased HDL concentrations, which is similar 
to the criteria used in cross-sectional studies by Hu et al.34, and Chattopadhyay and  Aldous35. The latter studies 
demonstrated that hypercholesterolaemia, hypertriglyceridaemia, and hypoalphalipoproteinaemia together with 
lipodystrophy were principal indices for dyslipidaemia among HIV-infected individuals after HAART  exposure35.
Genetic factors have been shown to contribute to dyslipidaemia in HIV-infected individuals on HAART. 
The present study identified five (5) SNPs (at position 86, 89, 97, 111 and 121) in LCAT exon 1 and one (1) SNP 
(at position 8) in LCAT exon 4. Out of the 6 SNPs identified in LCAT, only 1 SNP was clinically significant; a 
deletion of adenine (A) at position 97 of LCAT exon 1 in 32.5% of the sampled population. This study observed 
significant dyslipidaemia in participants with this SNP at position 97 of LCAT exon 1. The presence of this SNP 
results in a frameshift in the nucleotide sequence of the LCAT mRNA produced and hence a change in the amino 
acid sequence of the polypeptide produced (Supplementary Figs. S2, S3, and S4).
Protein modelling at ExPASy bioinformatic resource portal revealed that the deletion of adenine (A) at posi-
tion 97 of LCAT exon 1 leads to a shift in the open reading frame, resulting in the replacement of asparagine 
(N) with histidine (H) at position 5 of the mutant LCAT (Supplementary Figs. S2, S3, and S4, https ://www.expas 
y.org/prote omics /prote in_struc ture). This results in a change in the first 5 N-terminal amino acid sequences of 
the mature mutant LCAT . The 4 to 8 N-terminal amino acids located in the membrane-binding domain of the 
normal LCAT enzyme play a critical role in LCAT’s recognition, specificity, selectivity, and binding to apolipo-
protein A-I (ApoA-I) in HDL  particles36,37.
A change in the first 5 N-terminal amino acids, therefore, impairs the function of the membrane-binding 
domain of the mutant LCAT’s, affecting its ability to specifically recognize, select and bind to its substrate (HDL). 
This change in the type and sequence of the first five amino acids in the mutant LCAT’s structure severely 
impairs activation and catalytic activity of the mutant  enzyme38 accounting for the reduction in the rate of cho-
lesterol esterification and reverse transport to the liver for clearance from the body. The cholesterol therefore 
Table 5.  Comparison of lipid profile results amongst reference sequence and SNP populations. Unpaired t-test 
comparison of lipid profile parameters. †Denotes a significant comparison between reference population and 
SNP population when P-value is < 0.05, ++-† ††Denotes a significant comparison between reference population 
and SNP population when P-value is < 0.001. SEQ sequence, LDL low density lipoprotein, HDL high density 
lipoprotein, TRIG triglycerides, VLDL very low-density lipoprotein, CR coronary risk. FREQ frequency, ∆ 
change, LCAT lecithin cholesteryl acyl transferase, Data are presented as means ± SD, discrete, fractions and 
percentages. Reference population were defined as individuals with ‘normal’ nucleotide sequenced Whereas 
SNP population were those with nucleotide changes.
Nucleotide ∆ Exon POS
Reference population SNPs population
SEQ FREQ CHOL TRIG SEQ FREQ CHOL TRIG
Substitution 1
86 C*(35/40, 87.5%) 6.483 ± 1.512 1.337 ± 0.873 A (5/40, 12.5%) 4.538 ± 1.241 1.966 ± 1.609
89 G* (35/40, 87.5%) 4.982 ± 1.521 0.570 ± 0.255 A (5/40, 12.5%) 4.156 ± 0.887 1.572 ± 1.051
97 A*(27/40, 67.5%) 4.208 ± 1.119 1.339 ± 0.952 del (13/40, 32.5%) 6.272 ± 1.114
† 1.671 ± 1.213
111 C*(37/40, 92.5%) 4.684 ± 1.344 1.328 ± 0.838 A (3/40, 7.5%) 7.283 ± 0.719 2.917 ± 2.228
121 C*(35/40, 87.5%) 4.688 ± 1.368 1.337 ± 0.850 A (5/40, 12.5%) 6.214 ± 1.660†† 2.220 ± 1.886
Deletion 4 8 A*(4/46, 8.7%) 6.177 ± 2.154 0.727 ± 0.273 del (42/46, 91.3%) 4.842 ± 1.484 1.564 ± 1.005
SEQ FREQ HDL LDL SEQ FREQ HDL LDL
Substitution 1
86 C*(35/40, 87.5%) 1.071 ± 0.246† 3.331 ± 1.320 A (5/40, 12.5%) 0.881 ± 0.523 5.017 ± 1.407
89 G*(35/40, 87.5%) 0.969 ± 0.477 3.699 ± 1.546 A (5/40, 12.5%) 0.530 ± 0.430 3.120 ± 0.578
97 A*(27/40, 67.5%) 0.979 ± 0.408†† 2.985 ± 1.176 del (13/40, 32.5%) 883 ± 0.5280 4.958 ± 1.079
††
111 C*(37/40, 92.5%) 0.906 ± 0.506 3.459 ± 1.393 A (3/40, 7.5%) 1.013 ± 0.207 5.687 ± 0.458
121 C*(35/40, 87.5%) 0.902 ± 0.520 3.463 ± 1.421 A (5/40, 12.5%) 0.998 ± 0.155 4.772 ± 1.409
Deletion 4 8 A*(4/46, 8.7%) 1.393 ± 0.534 4.637 ± 2.195 del (42/46, 91.3%) 0.966 ± 0.513 3.563 ± 1.555
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accumulated in the body, leading to dyslipidaemia observed among the present study participants with this SNP. 
This is consistent with the findings of Francone and  Fielding39 who documented that, LCAT has amino (N) and 
carboxyl (C) terminal extensions that are not predicted to have significant secondary structure. However, the 
LCAT N-terminus amino acid residues 2 to 5 of the mature protein is known to be important for LCAT activity, 
mediating contacts with apolipoprotein A-I (ApoA-I) in HDL particles. The amino acid residues 2–5 represent the 
macromolecular interaction site for HDL  particles39. Murray et al.40 and Vanloo et al.41 documented in separate 
site-directed mutagenesis and antibody-binding experiments that, amino acid residues in the N-terminal region 
of LCAT play a structural role and ApoA-1’s binding to this site leads to the activation of LCAT.
This study’s findings also agree with the findings of Manthei et al.37 and Glukhova et al.36 who also docu-
mented that truncations in the N-terminus are critical for LCAT activity on HDL as it contains residues that are 
critical components of the HDL membrane-binding domain. Manthei et al.37 and Glukhova et al.36 also concluded 
that amino acid residues 4–8 have backbone amines that are critical for mediating interaction with ApoA-1 on 
HDL particles, substrate recognition, specificity, and selectivity.
Schindler et al.42 and Dube et al.43 also reported that LCAT glycoprotein has 4 N-glycosylation (Asn 20, 84, 
272, and 384) and 2 sites of O-glycosylation sites (Thr407 and Ser409). The carbohydrate component constitutes 
25% of LCAT’s total mass, the majority being N-linked44–46. Neuraminidase removal of the carbohydrate moiety 
of human LCAT led to a 60% decrease in the activity of the  enzyme42,45–47. Their finding supports the finding 
of this study that a change in a functional domain of LCAT affects the activity of the enzyme. The change in 
the first 5 amino acids decreases the activity of the mutant LCAT without affecting LCAT protein synthesis and 
 secretion42,44,48.
The influence of this SNP identified at position 97 of the mutant LCAT on plasma HDL cholesterol concentra-
tion is evidenced by the findings that hypoalphalipoproteinemia is one of the highest prevalent form of dyslipi-
demia present in this study. This shows the significant clinical influence of this SNP in inducing dyslipidaemia in 
HIV-infected individuals on HAART. In this study, 5 other SNPs (4 in LCAT exons 1 and 1 in exon 4) identified 
in LCAT do not have any significant effect on the dyslipidaemic outcomes in the study population. Twenty-five 
(25) SNPs were identified in LPL but none of these SNPs had a significant effect on the dyslipidaemic outcomes 
in the study population. This explains the observation that plasma triglycerides and VLDL concentrations did 
not change significantly after HAART.
Despite these findings, there were some limitations such as the sample size of the study was small, and SNPs 
present in other enzymes involved in the metabolism of lipids in the body were not sequenced. Also, the study 
did not longitudinally assess lipid parameters for the HIV-infected individuals which would have substantiated 
the association of SNPs presence and dyslipidaemia at baseline. Notwithstanding our observed findings are in 
line with previous reports.
Conclusion
The study has demonstrated the existence of SNPs in LCAT and LPL among HIV-infected individuals with 
dyslipidaemia in Ghana. The presence of SNPs at position 97 of LCAT exon 1 leads to the formation of a mutant 
LCAT which potentially reduces the rate of cholesterol esterification and reverse transportation to the liver for 
excretion. This supports the observation that reduced HDL-C was one of the commonest types of lipid abnormali-
ties among the study population. The SNPs identified in LPL did not significantly affect TG levels, supporting 
the observation that total triglycerides and VLDL concentrations did not change significantly after HAART. 
This study recommends the use of genotyping to prospectively identify individuals with SNPs that contribute 
to dyslipidaemia. Further longitudinal studies are required in larger HIV cohort to ascertain the findings in the 
present study.
 Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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